INTRODUCTION
). While we identified ASE sites within MAPT (Extended Data Fig. 8 and Supplementary Table   176 7), we also identified 4 sites of allele-specific expression in KANSL1 (Fig. 8a ), suggesting that the high 177 PD risk H1 allele is associated with lower KANSL1 expression, consistent with our functional 178 assessment. Interestingly, sequence analysis of the human KANSL1 haplotype revealed that the high 179 risk H1 haplotype is the more recent "mutant" specific to Homo sapiens, and that other primates 180 and mammals share the rarer non-risk ancestral H2 haplotype (Figure 8b ).
181
To assess the specificity of the KANSL1 KD effect on PINK1-mitophagy, 32 open reading 7 and Supplementary Table 8 ) were knocked down individually and their effect on pUb(Ser65) was 184 assessed. While the effect of KANSL1 KD on pUb(Ser65) was confirmed, neither the KD of MAPT, nor 185 the KD of each of the other 30 genes on this locus, led to a decreased in the pUb(Ser65) signal (Fig. 186 9). These data confirm the selectivity of our mitophagy screening assay and suggest that KANSL1 is 187 likely to be a key PD risk gene at the 17q21 locus. Since the first PD GWAS study was performed in 2006 33 GWAS have identified about 90 191 independent loci for PD 4 . However, translating GWAS findings into a new molecular understanding of PD-192 associated pathways and new therapeutic targets has remained a major challenge for the scientific 193 community. In order to screen for PD GWAS candidate genes that play a role in PINK1-mitophagy, and thus 194 are likely to be genuine risk genes for PD, we have set up and optimised a HCS for pUb(Ser65), a marker of 195 PINK1-dependent mitophagy, a key pathway in PD pathogenesis. This approach allowed the successful 196 identification of two new genes associated with increased PD risk, that play a role in mitophagy.
197
Interestingly, these two genes were previously shown to be part of the same complex, the NSL complex.
198
This study demonstrates the substantial potential of functional screens to exploit genetic data by 199 providing orthogonal information that can confidently identify new risk genes. This is particularly 200 important in genomic regions with uniformly high linkage disequilibrium, such as the 17q21 inversion 201 region which includes 32 ORFs of which many are highly expressed in brain and where existing fine-202 mapping and functional genomic analyses have been inconclusive. Interestingly, while MAPT has long been 203 considered the risk associated gene at this locus, this has recently been questioned by Dong and 204 colleagues, who also raised the significance of KANSL1 in driving PD risk at the locus 34 . Furthermore, 205 functional screening can simultaneously provide mechanistic insights as exemplified in this case by the 206 novel insights we provide into the molecular events regulating mitochondrial quality control and which 207 support a role for mitophagy as a contributing factor to sporadic PD. While our data demonstrate an 208 unequivocal role for KAT8 and KANSL1 in PINK1-dependent ubiquitin phosphorylation and subsequent 209 mitophagy, the precise mechanism of regulation remains to be determined. Our results identify KAT8 and 210 KANSL1 as modifiers of PINK1-dependent pUb(Ser65), suggesting that they may be regulating PINK1 kinase 211 activity. It will be important to determine whether phosphorylation of other PINK1 substrates, such as 212 Parkin and Rab8A 9,35 , are modulated by KAT8 and KANSL1. The KAT8 and KANSL1-containing NSL complex 213 functions to promote histone acetylation and as such, is a master regulator of transcription 36 . Therefore,
214
another possibility is that KAT8/KANSL1 may regulate PINK1 transcription, and subsequent translation.
9

METHODS
236
Reagents
237
Oligomycin (mitochondrial complex V inhibitor) was purchased from Cayman Chemicals (11341) and 238 from Sigma-Aldrich (O4876), and antimycin A (mitochondrial complex III inhibitor) was purchased 239 from Sigma-Aldrich (A8674). All siRNAs were purchased as pre-designed siGENOME SMARTpools 
253
Selection of genes for High Content Screening
254
Candidates for High Content Screening were selected based on i) WPPINA; ii) complex prioritization; 255 and, iii) coloc analysis. WPPINA analysis is reported in 18 where the 2014 PD GWAS 19 was analysed; 256 candidate genes where selected among those prioritised and with an LD r2 ≥ 0.8. The same pipeline 257 has then been additionally applied to the 2017 PD GWAS 3 to update the list of candidate genes.
258
Briefly, a protein-protein interaction network has been created based on the Mendelian genes for 259 PD (seeds) using data from databases within the IMEx consortium. The network has been 260 topologically analysed to extract the core network (i.e. the most interconnected part of the 261 network). The core network contains the proteins/genes that can connect >60% of the initial seeds 262 and are therefore considered relevant for sustaining communal processes and pathways, shared by 
265
in cis-haplotypes defined by LD r2 ≥ 0.8 (analysis performed in October 2017) 3 . These ORFs have 266 been matched to the core network to identify overlapping proteins/genes in relevant/shared 267 pathways. Results of complex prioritization (neurocentric prioritization strategy) were gathered from 268 10 3 where this strategy was applied to the 2017 PD GWAS 3 . The coloc analysis was performed as 269 reported in 17 , posterior probabilities for the hypothesis that both traits, the regulation of expression 270 of a given gene and the risk for PD share a causal variant (PPH4), were calculated for each gene, and 271 genes with PPH4 ≥ 0.75 were considered to have strong evidence for colocalization. Summary 272 statistics were obtained from the most recent PD GWAS 4 and were used for regional association 
283
Sites of ASE were identified as described by Guelfi and colleagues 32 by mapping RNA-seq data to 284 personalised genomes, an approach specifically chosen because it aims to minimise the impact of 285 mapping biases. RNA-seq data generated from 49 putamen and 35 substantia nigra tissue samples 286 from the UK Brain Expression Consortium was used for this analysis. All samples were obtained from 287 neuropathologically normal individuals of European descent and sites with greater than 15 reads in a 288 sample were tested for ASE. Only sites present in non-overlapping genes were considered and data 289 from both the tissues were considered together to increase power. Sites with minimum FDR < 5% 290 across samples were marked as ASE sites. Plots were generated using Gviz3, with gene and 291 transcript details obtained from Ensembl v92. 11 Cells were fixed with 4% PFA (Sigma-Aldrich, F8775), then blocked and permeabilised with 10% FBS, 303 0.25% Triton X-100 in PBS for 1 h, before immunostaining with pUb(Ser65) and TOM20 primary 304 antibodies (in 10% FBS/PBS) for 2 h at room temperature. After 3x PBS washes, AlexaFluor 568 anti-305 mouse and 488 anti-rabbit secondary antibodies and Hoechst 33342 (Thermo Scientific, 62249) were 306 added (in 10% FBS/PBS, 1:2000 dilution for all) and incubated for 1 h at room temperature.
307
Following a final 3x PBS washes, plates were imaged using the Opera Phenix (Perkin Elmer). 5x fields 308 of view and 4x 1 µm Z-planes were acquired per well, using the 40X water objective, NA1.1. Images
309
were analysed in an automated way using the Columbus 2. 
364
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